You just read:

FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis

News provided by

Amgen

Feb 07, 2017, 18:13 ET